Musunuru provided ESGCT delegates with promising news of a roadmap following the diagnosis and treatment of Baby KJ.
In April 2025, AstraZeneca announced that its experimental oral PCSK9 inhibitor, AZD0780, achieved a 50.7% reduction in LDL ...
CRISPR therapies offer precise gene-editing solutions for treating genetic disorders and other complex diseases. Rising prevalence of genetic conditions drives adoption, and emerging CRISPR-based ...
AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...